Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2018

  • ID: 4590337
  • Report
  • 94 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Biogen Inc
  • Bristol-Myers Squibb Co
  • Coronis NeuroSciences Ltd
  • F. Hoffmann-La Roche Ltd
  • Iproteos SL
  • MORE
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2018, provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline landscape.

Cognitive functioning is moderately to severely impair in patients with schizophrenia. Symptoms include poor executive functioning, inability to sustain attention and problems with working memory. Predisposing factors include family history, age and autoimmune diseases. Treatment includes antipsychotic medications.

Report Highlights:

This latest pipeline guide Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 10, 8, 12 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Biogen Inc
  • Bristol-Myers Squibb Co
  • Coronis NeuroSciences Ltd
  • F. Hoffmann-La Roche Ltd
  • Iproteos SL
  • MORE
Introduction

Report Coverage

Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview

Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cognitive Impairment Associated With Schizophrenia (CIAS) - Companies Involved in Therapeutics Development

Astellas Pharma Inc

AstraZeneca Plc

Biogen Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Cadent Therapeutics

Coronis NeuroSciences Ltd

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

Heptares Therapeutics Ltd

Intra-Cellular Therapies Inc

Iproteos SL

Pfizer Inc

Sage Therapeutics Inc

SK Biopharmaceuticals Co Ltd

Spherium Biomed SL

Takeda Pharmaceutical Co Ltd

Vanda Pharmaceuticals Inc

Cognitive Impairment Associated With Schizophrenia (CIAS) - Drug Profiles

ASP-4345 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-5736 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-6981 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUT-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUT-6 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUT-9 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVL-3288 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

basmisanil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-425809 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIIB-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-955829 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CP-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

davunetide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erteberel - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTL-18318 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTL-9936 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IC-041 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IPR-19 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ITI-214 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LSN-2814617 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-03463275 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SGE-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKL-20540 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize NMDA2B for Cognitive Impairment Associated with Schizophrenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Modulate CHRM for Central Nervous System and Respiratory Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SP-14040 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVND-4010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVNG-3031 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-041 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-831 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VQW-765 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0467154 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects

Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products

Cognitive Impairment Associated With Schizophrenia (CIAS) - Product Development Milestones

Featured News & Press Releases

Feb 01, 2015: ASCIL Biopharm cooperates in a Project awarded with a “RETOS-Colaboración” grant

Jan 27, 2015: Spark, a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia

Apr 17, 2013: SK Biopharma Announces FDA's Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Astellas Pharma Inc, H2 2018

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AstraZeneca Plc, H2 2018

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Biogen Inc, H2 2018

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Boehringer Ingelheim GmbH, H2 2018

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Bristol-Myers Squibb Co, H2 2018

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Cadent Therapeutics, H2 2018

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Coronis NeuroSciences Ltd, H2 2018

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Eli Lilly and Co, H2 2018

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Heptares Therapeutics Ltd, H2 2018

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Intra-Cellular Therapies Inc, H2 2018

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Iproteos SL, H2 2018

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Pfizer Inc, H2 2018

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Sage Therapeutics Inc, H2 2018

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2018

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Spherium Biomed SL, H2 2018

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Vanda Pharmaceuticals Inc, H2 2018

Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H2 2018

Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H2 2018 (Contd..1), H2 2018

Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Biogen Inc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Cadent Therapeutics
  • Coronis NeuroSciences Ltd
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • Heptares Therapeutics Ltd
  • Intra-Cellular Therapies Inc
  • Iproteos SL
  • Pfizer Inc
  • Sage Therapeutics Inc
  • SK Biopharmaceuticals Co Ltd
  • Spherium Biomed SL
  • Takeda Pharmaceutical Co Ltd
  • Vanda Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll